TrialJournal of hematology & oncology2026

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Guillaume Cartron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.